Drug intelligence / Profile preview

azithromycin + loperamide

Development stage
Unknown
Lead developer
PLIVA
Modality
Small Molecules
Administration
Oral
01

Overview

Azithromycin + loperamide is a combination therapy used primarily for the treatment of travelers' diarrhea. Clinical studies have demonstrated that this combination significantly reduces the duration of diarrhea compared to azithromycin alone. In a prospective, double-blinded, randomized trial conducted in Mexico, the combination therapy shortened the duration of diarrhea to approximately 11 hours compared to 34 hours with azithromycin monotherapy. The combination also resulted in fewer unformed stools within the first 24 hours post-treatment (1.2 versus 3.4 with azithromycin alone). Azithromycin is a macrolide antibiotic that targets bacterial pathogens causing diarrhea, while loperamide is an antidiarrheal agent that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and reduce fluid loss. This combination is particularly effective in regions where Escherichia coli is the predominant cause of travelers' diarrhea.

Brand names
ImodiumZithromax
Other names
azithromycin plus loperamideloperamide plus azithromycin
02

Targets

MOR (Mu opioid receptor)Bacterial 50S ribosomal subunitABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on azithromycin + loperamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + loperamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call